Regeneron’s Eylea: A Game Changer for Treatment of Macular Degeneration?
August 22, 2012
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) began selling Eylea late last year for treatment of wet macular degeneration.
Recently, the American Journal of Ophthalmology published a review of the medical literature and pertinent Internet postings combined with analysis of key studies with expert opinion regarding the use of Eylea (a/k/a aflibercept) for the treatment of wet AMD.
The authors concluded that Eylea promises to deliver excellent visual outcomes for wet age-related macular degeneration patients while undergoing fewer injections compared with Lucentis (a/k/a ranibizumab). With a wholesale cost of $1850 per dose, the cost per patient with Eylea treatment promises to be lower than with Lucentis.
Click here for access to the abstract.
You might also enjoy...
- Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for Wet Age-Related Macular Degeneration
- Regeneron’s EYLEA® Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Europe
- Avastin Compares to Lucentis
- Study Shows Fovista Administered in Combination With Lucentis Yields Better Results Treating Wet AMD Than Lucentis Alone
- Combining XIBROM(TM) and Lucentis May Provide Added Efficacy Over Lucentis Alone in Treating Neovascular Age-Related Macular Degeneration
Comments
Jump down to form below to submit your own comments
